eFT226,sotorasib,Abemaciclib,zotatifin
effector therapeutics,amgen,eli lilly
['abemaciclib', 'bcsm', ' fulv', 'zotatifin', 'abema']
in the dose-expansion study, zotatifin was examined as a doublet with fulvestrant and as a triplet with fulvestrant and abemaciclib. the confirmed orr with the doublet was 5.9%. #bcsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.